Shire helps ArmaGen develop AGT182 for Hunter syndrome
Executive Summary
ArmaGen Technologies Inc. (therapies for neurological conditions) enlisted the help of Shire PLC to develop its enzyme replacement therapy (ERT) AGT182 for central nervous system and somatic manifestations of Hunter syndrome.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice